The ADVANCE Study is recruiting seniors 65 to 90 years of age who have been diagnosed with Alzheimer’s disease and are experiencing agitation symptoms to take part in a clinical research study. The purpose of the study is to determine the safety and effectiveness of an investigational medication for agitation in patients with Alzheimer’s disease.
Individuals will be evaluated to determine their eligibility to participate in the study. If eligible, study participants will receive the study drug (AXS-05), an active control (bupropion), or a placebo control (inactive substance) orally as a tablet taken twice daily for five consecutive weeks. All three products look identical, but only AXS-05 contains the active drug intended to treat your loved one’s agitation. Study participants will also receive study-related medical exams and laboratory tests at no cost. Compensation for time and travel may also be available.
Learn more about the ADVANCE Study.